ArticleCurrent oncology (Toronto, Ont.)2026

Re-Exposure of a PD-1 Inhibitor After Previous Immune-Related Adverse Events.

Jana Burghaus-Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.